$3m · Seed · Software · London, UK
London-based Pharosyn has raised a $3m seed round led by Moonfire, with participation from Entrepreneurs First, Transpose Platform and General Advance. The company is building AI infrastructure for commercial decision-making in pharmaceutical businesses, spanning portfolio strategy, business development and licensing, market research, forecasting and competitive intelligence.
The financing gives Pharosyn more room to expand a product built around a recurring information problem. Pharma commercial teams monitor clinical and regulatory events, deals, hiring, epidemiology and other signals, then turn them into reports and decisions about products and portfolios. Pharosyn says its system automates that monitoring, filters it to a customer’s priorities and produces deliverables in the customer’s preferred format.
Pharosyn reports a 94% average reduction in time to deliver work compared with legacy vendors, including a benchmark that cuts a four-hour task to 14 minutes. It also says senior directors at top-10 pharmaceutical companies use the platform daily. Those figures are company-reported rather than independently audited, but they illustrate the commercial pitch: reduce the manual work between an external event and a decision-ready explanation.
A decision system has to preserve the evidence trail
Speed alone is a weak proposition in regulated and high-stakes workflows if users cannot inspect how an answer was produced. Pharosyn says every AI output is traceable to its source data, customer data is not used to train models, and the foundation models used for inference are tracked and pinned. That makes verification part of the product rather than a separate clean-up step.
The company’s delivery model is also deliberately hands-on. Pharosyn describes its team as forward-deployed, working with customers to build a first system in weeks inside the customer’s environment, then adding custom modules and data connections on top of a shared technical core. This can help the product fit specialised workflows that generic assistants struggle to capture.
Custom deployment is both the wedge and the test
That implementation model may create strong customer ties because the software is embedded in how teams monitor markets and make portfolio decisions. It also introduces an execution question for the seed stage: how much of each deployment can become repeatable software, and how much remains expert services and engineering work.
The round therefore tests more than demand for pharma-focused AI. Pharosyn must show that its traceability, data controls and configurable workflows can scale across customers without losing the domain fit that won the work in the first place. Founders Stephen Cowley and Joshua Hampson combine backgrounds in AI research and biochemistry, while the wider team says it brings pharmaceutical strategy and enterprise engineering experience. Moonfire founder Mattias Ljungman framed the investment around the founders’ technical depth and ambition.
